← Back
No items found.
December 9, 2020

New board member

PharmNovo is pleased to announce that Helen Pettersson is now a member of the board, representing Almi Invest and Almi Invest Syd, being one of the larger investors in PharmNovo AB.

Helen works as an Investment manager at Almi Invest South. She focuses on Life Science and is responsible for the entire investment process at Almi. Currently, she is the investment manager of four of Almi Invest South’s portfolio companies and a board member of two companies.

Helen has a PhD in Tumor Immunology and began her career as a translational cancer researcher. She has for several years worked with project management and network platforms for life science stakeholders from academia, industry and healthcare. Before joining Almi Invest, Helen was a Senior project manager at the Danish-Swedish cluster organization Medicon Valley Alliance and before that a Senior project manager at the science park Medicon Village.

PharmNovo is welcoming Helen to the team!

December 9, 2020

New board member

PharmNovo is pleased to announce that Helen Pettersson is now a member of the board, representing Almi Invest and Almi Invest Syd, being one of the larger investors in PharmNovo AB.

Helen works as an Investment manager at Almi Invest South. She focuses on Life Science and is responsible for the entire investment process at Almi. Currently, she is the investment manager of four of Almi Invest South’s portfolio companies and a board member of two companies.

Helen has a PhD in Tumor Immunology and began her career as a translational cancer researcher. She has for several years worked with project management and network platforms for life science stakeholders from academia, industry and healthcare. Before joining Almi Invest, Helen was a Senior project manager at the Danish-Swedish cluster organization Medicon Valley Alliance and before that a Senior project manager at the science park Medicon Village.

PharmNovo is welcoming Helen to the team!

Author:

Petra Larson

Author:

Petra Larson

A stronger team

We are pleased to announce that we have hired Jesper Kjerulff, starting on June 1st, to serve as the project leader for the continued development of our candidate compound PN6047 and lead the project into phase 1 clinical trials in Q2 2022.

Read more →

In memory of Hans G.

Hans G. Nilsson, PhD (1943–2021), has during a cross country ski trip on a beautiful Sunday in January 2021, unexpectedly left us in grief and mourning.

Read more →

Patent granted in China

We are pleased to announce that PharmNovo AB has been granted a patent for our candidate PN6047 in China. PharmNovo AB is currently entering into regulatory toxicology studies with PN6047 – an exciting phase in the development of this biased delta opioid receptor agonist (DOBRA) favouring signalling through G proteins. In preclinical testing, our candidate effectively reduces neuropathic pain without any of the unwanted side effects of conventional opioids.

Read more →

22 MSEK new funding

PharmNovo has completed a new share issue of 22 million SEK with the Sciety investment syndicate as the lead investor.

Read more →
Latest
breaking
news

Find us

PharmNovo AB
Medicon Village AB
Scheeletorget 1
SE-223 81 Lund, Sweden

Map